Please login to read the full article.
Scrip Regulatory Affairs
Sins of omission: how the US FDA's social media inaction puts patients and industry at risk
04 May 2011
Bill Drummy
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EU pharmacovigilance legislation implementation likely to be staggered
- European industry bodies voice concern over CoE's anti-counterfeiting system
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- US senator looks to 80/20 mantra to save PDUFA V
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
